15:09 , Sep 1, 2017 |  BC Week In Review  |  Financial News

AAT deficiency newco Apic Bio launches

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Aug. 22 with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said its...
22:44 , Aug 22, 2017 |  BC Extra  |  Financial News

AAT deficiency newco Apic Bio launches

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Tuesday with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said its lead...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Inhibrx, Alpha-1 Foundation deal

Inhibrx and Alpha-1’s Alpha-1 Project Inc. subsidiary partnered to develop a recombinant alpha-1 antitrypsin (AAT) therapeutic. Alpha-1 will make an undisclosed equity investment in Inhibrx, which is developing AAT-Fc. The recombinant AAT (...
07:00 , Oct 12, 2015 |  BioCentury  |  Regulation

Learning in liver

Jennifer Rhodes, Staff Writer   Patients and caregivers at FDA's patient-focused drug development meeting on alpha-1 antitrypsin deficiency are desperate for treatments for liver-affected patients, whose only option is a transplant. With two RNAi programs now...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Alnylam Pharmaceuticals Inc, Alpha-1 Foundation deal

The foundation’s wholly owned for-profit venture subsidiary, The Alpha-1 Project (TAP), is funding an undisclosed portion of Alnylam’s development of ALN-AAT to treat alpha 1-antitrypsin (AAT; A1AT; SERPINA1) deficiency-associated liver disease. Alnylam...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Alpha-1 Foundation endocrine/metabolic news

Healthcare financial firm Poliwogg partnered with the foundation's wholly owned for-profit venture subsidiary, The Alpha-1 Project, to encourage investment in research for treatments for alpha 1-antitrypsin deficiency. Poliwogg provides pathways for investors to invest in...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Alpha-1 Foundation, UMMS endocrine/metabolic news

The not-for-profit's The Alpha-1 Project (TAP) Inc. subsidiary provided an undisclosed grant to the medical school to develop its PiZ antibody. The partners said the antibody will be used to track the presence of the...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Carolus, Alpha-1 Foundation deal

Carolus partnered with the not-for-profit's The Alpha-1 Project (TAP) Inc. subsidiary to characterize human biological samples for the presence of chemokine CC motif ligand 5 ( RANTES; CCL5)- platelet factor 4 ( PF4;...
02:19 , Feb 14, 2009 |  BC Extra  |  Politics & Policy

FDA to hold alpha 1-antitrypsin workshop

FDA, the not-for-profit Alpha-1 Foundation and HHS's Office of Public Health and Science will hold a public workshop March 23-24 to discuss clinical efficacy endpoints for alpha 1-antitrypsin ( AAT, A1AT) augmentation therapy. AAT deficiency...